-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

UBS Downgrades Cano Health to Neutral, Lowers Price Target to $1.25

Benzinga · 01/06/2023 07:55
UBS analyst Andrew Mok downgrades Cano Health (NYSE:CANO) from Buy to Neutral and lowers the price target from $12 to $1.25.